Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
5 Results for "
B7-H4-expressing cells
" in MedChemExpress (MCE) Product Catalog:
Products (5)
5 Results for "B7-H4-expressing cells" in MCE Product Catalog:
Cat. No.: HY-171689
CAS No.: 2760250-80-2
Synonyms: AZD 8205; P-Sam
Research Areas:
Puxitatug samrotecan (AZD 8205) is an antibody-drug conjugate (ADC) targeting B7-H4, formed by the random conjugation of the Puxitatug (HY-P990059) antibody and AZ14170133 (HY-145399) via interchain cysteine reduction. Puxitatug samrotecan binds to B7-H4 to deliver the payload to B7-H4-expressing cells, inhibits topoisomerase I, and induces cytotoxicity in cancer cells and xenograft models. Puxitatug samrotecan can be used in studies of B7-H4-expressing tumors .
Cat. No.: HY-P990059
CAS No.: 2760250-47-1
Synonyms: INT-016; AZD8205 Antibody
Target:
Research Areas:
Cat. No.: HY-P990953
CAS No.: 2640279-10-1
Synonyms: Gen1047
Cat. No.: HY-185280
CAS No.: 3042848-25-6
Synonyms: HS-20089 (DAR6); GSK5733584 (DAR6)
Research Areas:
Mocertatug rezetecan (DAR6) (HS-20089 (DAR6); GSK5733584 (DAR6)) is an antibody-drug conjugate (ADC) targeting B7-H4, composed of Mocertatug (HY-P991703) and MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan (HY-148668). Mocertatug rezetecan (DAR6) delivers a TOPO1 inhibitor payload. It binds to B7-H4-expressing tumor cells, triggers ADC internalization, and induces S-phase cell cycle arrest, cytotoxicity, and bystander killing effect. Mocertatug rezetecan (DAR6) exhibits dose-dependent tumor growth inhibition in breast cancer and endometrial cancer CDX models. It can be used in research related to platinum-resistant ovarian cancer, breast cancer, endometrial cancer, cholangiocarcinoma, and cervical cancer .
Cat. No.: HY-185280A
CAS No.: 3042848-25-6
Synonyms: HS-20089 (DAR4); GSK5733584 (DAR4)
Research Areas:
Mocertatug rezetecan (DAR4) (HS-20089 (DAR4); GSK5733584 (DAR4)) is an antibody-drug conjugate (ADC) targeting B7-H4, composed of Mocertatug (HY-P991703) and MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan (HY-148668). Mocertatug rezetecan (DAR4) delivers a TOPO1 inhibitor payload. It binds to B7-H4-expressing tumor cells, triggers ADC internalization, and induces S-phase cell cycle arrest, cytotoxicity, and bystander killing effect. Mocertatug rezetecan (DAR4) exhibits dose-dependent tumor growth inhibition in breast cancer and endometrial cancer CDX models. It can be used in research related to platinum-resistant ovarian cancer, breast cancer, endometrial cancer, cholangiocarcinoma, and cervical cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
